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Abstract: The aim of this study was to first evaluate whether the chitosan hydrochloride-
genipin crosslinking reaction is influenced by factors such as time, and polymer/genipin 
concentration, and second, to develop crosslinked drug loaded microspheres to improve the 
control over drug release. Once the crosslinking process was characterized as a function of 
the  factors  mentioned  above,  drug  loaded  hydrochloride  chitosan  microspheres  with 
different degrees of crosslinking were obtained. Microspheres were characterized in terms 
of size, morphology, drug content, surface charge and capacity to control in vitro drug 
release.  Clarithromycin,  tramadol  hydrochloride,  and  low  molecular  weight  heparin 
(LMWH)  were  used  as  model  drugs.  The  obtained  particles  were  spherical,  positively 
charged,  with  a  diameter  of  1–10  μm.  X-Ray  diffraction  showed  that  there  was  an 
interaction of genipin and each drug with chitosan in the microspheres. In relation to the 
release profiles, a higher degree of crosslinking led to more control of drug release in the 
case  of  clarithromycin  and  tramadol.  For  these  drugs,  optimal  release  profiles  were 
obtained for microspheres crosslinked with 1 mM genipin at 50 º C for 5 h and with 5 mM 
genipin at 50 º C for 5 h, respectively. In LMWH microspheres, the best release profile 
corresponded to 0.5 mM genipin, 50 º C, 5 h. In conclusion, genipin showed to be eligible 
as a chemical-crosslinking agent delaying the outflow of drugs from the microspheres. 
However, more studies in vitro and in vivo must be carried out to determine adequate 
crosslinking conditions for different drugs.  
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1. Introduction  
Among  others,  marine  organisms  continue  to  attract  significant  interest  as  potential  sources  of 
compounds with beneficial pharmacological activities. Among marine origin compounds, chitosan, a 
biopolymer  obtained  as  a  result  of  deacetylation  of  chitin,  mainly  obtained  from  crustacean 
exoeskeleton, has gained interest as a biocompatible and biodegradable matrix for drug controlled 
release and has been the subject of numerous studies in the last decades [1]. The hydrosoluble chitosan 
derivative, chitosan hydrochloride, was approved by Pharmacopea Europaea in 2002.  
The use of crosslinking agents is considered a relevant tool to improve the control in drug delivery. 
Among  other  reagents,  glutaraldehyde  and  tripolyphosphate  have  been  widely  used  to  crosslink 
biodegradable  polymers.  However,  there  are  concerns  over  the  toxicity  of  the  most  studied  
cross-linking agents, especially glutaraldehyde, which may impair the biocompatibility of the chitosan 
delivery  system  [2],  and  therefore,  there  is  a  need  to  provide  a  crosslinking  agent  that  has  
low cytotoxicity.  
Geniposide is extracted from the fruit of Gardenia jasminoides Ellis, traditionally used in oriental 
medicine for the treatment of inflammation, headache, and hepatic disorders among others [3]. Its 
aglycone,  genipin  (Figure  1),  has  recently  attracted  much  interest  as  a  crosslinking  agent  for 
biomedical  use  because  of  its  biocompatibility  and  because  it  forms  stable  and  biocompatible 
crosslinked products [4,5]. The formation of crosslinks between genipin and primary amine groups [5] 
and  the  finding  that  genipin-crosslinked  networks  are  significantly  less  cytotoxic  than  those 
crosslinked by glutaraldehyde [6] prompted us to use this chemical as a crosslinking agent to develop 
chitosan microspheres for controlled drug release. 
Figure 1. The chemical structure of genipin. 
 
In this study, the influence of some conditions (time, genipin concentration) over the crosslinking 
reaction was studied. Once the crosslinking process was characterized, microspheres with different 
degree of crosslinkage were obtained. Three different drugs, a macrolid antibiotic, clarithromycin, an 
analgesic drug, tramadol hydrochloride, and low molecular weight heparin (LMWH), were used as 
model drugs. Microspheres were studied in terms of size, morphology, drug content, surface charge 
and capacity to control drug release.  Mar. Drugs 2010, 8                            
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2. Results and Discussion  
2.1. Characterization of the crosslinking reaction 
In this study, genipin, a natural crosslinking agent, was used to crosslink chitosan microspheres to 
evaluate its effect on drug release. Genipin reacts with compounds containing primary amine groups, 
such as chitosan and some peptides and polypeptides, to form covalently crosslinked networks [7–10]. 
In the case of chitosan, genipin reacts with the free amino groups present in the glucosamine units. It 
has been reported that two separate reactions lead to the crosslinking between these two compounds 
[5]. The reaction between chitosan hydrochloride and genipin in solution was characterized by UV 
spectra analysis before spray-drying. The influence of reaction time and genipin concentration on the 
crosslinking reaction was studied.  
Genipin  dissolved  in  water  displayed  an  absorption  peak  at  240  nm,  which  was  higher  with 
increased genipin concentrations. After the addition of chitosan to the genipin solution, the absorption 
at 240 nm decreased and a new absorption peak at 290 could be seen. This absorption peak increased 
with reaction time and genipin concentration (Figure 2). Mi and co-workers [7] described that this 
decrease at 240 nm was due to the conversion of the ester group of genipin into an amide linkage 
formed after the nucleophilic attack by chitosan amino groups. On the other hand, the increase at 
290  nm  was  attributed  to  the  formation  of  the  heterocyclic  genipin-chitosan  compound  [11].  The 
presence of this peak and its increase with reaction time and genipin concentration is therefore an 
indication of the extent of the crosslinking between genipin and chitosan.  
Figure 2. (A). UV spectra of Chitosan hydrochloride (HCS) (5 mg/mL)–genipin (Gnp)  
(5  mM)  solutions  incubated  at  50  º C  for  different  crosslinking  periods  (30  min–7  h).  
(B). UV spectra of HCS (5 mg/mL)–Gnp solutions incubated at 50 º C for 5 h with different 
concentrations of genipin (0.5, 1, 2 and 5 mM). 
 
The  effect  of  increasing  the  concentration  of  genipin  on  the  crosslinking  reaction  at  fixed 
temperature, 50 º C (based  on previous studies  carried  out  in our laboratory) and time (5 h), was 
evaluated.  In  the  same  way,  different  reaction  times  (0–30  min)  at  50  º C  and  fixed  genipin 
concentration (5 mM) were studied in relation to the crosslinking process. As shown in Figure 2, both 
increasing  genipin  concentration  and  reaction  time  led  to  a  higher  degree  of  crosslinking.  For 
biomedical  applications,  the  adequate  crosslinking  conditions  should  be  studied  in  each  case 
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depending on the drug, location of release within the human body, and pharmacokinetic parameters, to 
achieve optimal controlled release. 
2.2. Scanning electron microscopy (SEM)  
Figure 3 shows the morphology of chitosan microspheres crosslinked with genipin and loaded with 
clarithromycin (Figure 3A), tramadol hydrochloride (Figure 3B) or LMWH (Figure 3C) obtained by 
SEM. As can be seen, <10 m microspheres were obtained in all cases. The obtained microspheres 
presented a smooth surface with indentations as a result of rapid particle shrinking during the drying 
process [12].  
Figure  3.  Scanning  electron  micrographs  of  chitosan  hydrochloride  microspheres.  
(A). Chitosan microspheres loaded with 50% (w/w) clarithromycin crosslinked with 1 mM 
genipin for 5 h at 50 º C. (B). Chitosan microspheres loaded with 30% (w/w) tramadol 
hydrochloride crosslinked with 2 mM genipin for 5 h at 50 º C. (C). Chitosan microspheres 
loaded with 10% (w/w) LMWH crosslinked with 0.5 mM genipin at 50 º C for 5 h. 
 
2.3. Zeta potential 
The  zeta  potential  of  the  microspheres  is  shown  in  Table  1  (microspheres  loaded  with 
clarithromycin),  Table  2  (microspheres  loaded  with  tramadol  hydrochloride)  and  Table  3 
(microspheres loaded with LMWH).  
As can be seen with these three cases, the zeta potential values decreased when the microspheres 
were  crosslinked  with  genipin,  proving  the  genipin-polymer  interaction.  Nevertheless,  all  the 
microspheres  showed  positive  charge,  so  all  of  them  maintained  the  chitosan  mucoadhesive  and 
absorption enhancement properties and can be considered as potential drug release vehicles [13]. 
Table 1. Zeta potential (mV) of chitosan hydrochloride (5 mg/mL) microspheres with 50% 
(w/w) clarithromycin without genipin (C1) and crosslinked with 0.5 mM genipin (C2) and 
1 mM genipin (C3) at 50 ºC  for 5 h. 
Microspheres  Genipin 
mM 
Crosslinking time 
(hours) 
Zeta Potential 
mV 
C1  0  0  49.3 ±  5.4 
C2  0.5  5  38.6 ±  1.10 
C3  1  5  32.9 ±  2.15 
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Table 2. Zeta potential (mV) of chitosan hydrochloride (5 mg/mL) microspheres with 30% 
(w/w) tramadol hydrochloride without genipin (T1) and crosslinked with 2 mM genipin 
(T2) and 5 mM genipin (T3) at 50 ºC  for 5 h. 
Microspheres  Genipin 
mM 
Crosslinking 
time (hours) 
Zeta Potential 
mV 
T1  0  0  24.6 ±  3.15 
T2  2  5  14.84 ±  1.06 
T3  5  5  14.50 ±  0.46 
Table 3. Zeta potential (mV) of chitosan hydrochloride (1 mg/mL) microspheres (HCS), 
chitosan  hydrochloride-LMWH  microspheres  (HB)  and  chitosan  hydrochloride-LMWH 
microspheres, crosslinked with different genipin concentration (HGBa-HGBf) at 50 ºC  for 
0, 5 or 15 h. 
Microspheres  Genipin  
mM 
Crosslinking time 
(hours) 
Zeta Potential  
mV 
HCS   0  0  25.51 ±  0.69 
HB  0  0  23.04 ±  0.96 
HGBf  2.5  0  19.95 ±  0.99 
HGBd  0.5  5  14.68 ±  2.52 
HGBc  0.5  15  12.21 ±  0.76 
HGBb  12.5  15  10.36 ±  0.84 
HGBa  25  15  7.42 ±  0.23 
2.4. Drug-polymer interaction 
The  X-Ray  diffraction  patterns  of  genipin,  chitosan  hydrochloride,  assayed  drugs,  and  the 
combination  of  all  microsphere  components  are  shown  in  Figures  4–6.  Genipin  itself,  as  well  as 
clarithromycin and tramadol hydrochloride, showed high crystallinity. On the other hand, the chitosan 
hydrochloride  X-ray  pattern  showed  its  amorphous  structure.  Genipin,  as  well  as  clarithromycin 
(Figure 4) and tramadol hydrochloride (Figure 5) are included in the amorphous structure of chitosan 
when incorporated in microspheres. As can be seen in Figure 6, the LMWH X-ray pattern shows it as 
an  amorphous  compound.  LMWH  loaded  microspheres  crosslinked  with  genipin  show  an  X-ray 
diffraction pattern with no marked peaks, which indicates that the crosslinking agent is molecularly 
dispersed in the polymer matrix [14,15], which should help to retard the delivery of the drug [16].  Mar. Drugs 2010, 8                            
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Figure  4.  X-ray  diffraction  patterns  of  (a)  genipin,  (b)  clarithromycin,  (c)  chitosan 
hydrochloride,  (d)  chitosan  hydrochloride  (5  mg/mL)  microspheres  loaded  with 
clarithromycin (50% w/w) and crosslinked with genipin (1 mM) at 50 º C for 5 h. 
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Figure  5.  X-ray  diffraction  patterns  of  (a)  tramadol  hydrochloride  and  (b)  chitosan 
hydrochloride (5 mg/mL) microspheres loaded with tramadol hydrochloride (30% w/w) 
and crosslinked with genipin (2 mM) at 50 º C for 5 h. 
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Figure  6.  X-ray  diffraction  patterns  of  (a)  low  molecular  weight  heparin,  LMWH  
(b) chitosan hydrochloride (1 mg/mL) microspheres loaded with LMWH (10% w/w) and 
crosslinked with genipin (0.5 mM) at 50 º C for 5 h. 
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2.5. Drug release studies 
As mentioned in the experimental section, preliminary studies using different times, temperatures, 
and  genipin  concentrations  were  carried  out  for  assayed  drugs.  5  h  and  50  º C  were  revealed  as 
adequate time and temperature conditions to achieve the desired degree of crosslinking. The genipin 
concentration  range  used  for  each  drug  is  also  a  consequence  of  these  previous  results  (data  
not shown). 
The  encapsulation  efficiency  was  >85%  for  clarithromycin,  >90%  for  tramadol,  and  15–30% 
depending on the crosslinking degree (the higher the crosslinking degree the lesser the encapsulation 
efficiency) in the case of LMWH. 
2.5.1. Clarithromycin 
The effect of crosslinking microspheres with genipin on clarithromycin release in simulated gastric 
fluid (SGF) was studied. The addition of the crosslinking agent led to the slower release of the drug.  
Figure 7 shows clarithromycin release profiles of non crosslinked chitosan microspheres and from 
microspheres crosslinked with 1 mM genipin for 5 h at 50 º C. After 3 h, microspheres without genipin 
had released 100% of the drug, while crosslinked microspheres had released 60% of clarithromycin. 
The release from microspheres crosslinked with 0.5 mM genipin did not show significant differences 
with microspheres with 1mM genipin (results not shown).  
Figure  7.  Release  profiles  of  clarithromycin  in  SGF  from  chitosan  hydrochloride  
(5 mg/mL) microspheres loaded with clarithromycin (50% w/w) without genipin (0 mM) 
and crosslinked with 1mM genipin at 50 º C for 5 h. 
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2.5.2. Tramadol hydrochloride 
The  effect  of  genipin  concentration  (0  mM,  2  mM  and  5  mM)  on  the  release  of  tramadol 
hydrochloride from chitosan microspheres is shown in Figure 8. As can be seen, drug release was 
slower in the case of microspheres crosslinked with genipin in comparison with the non crosslinked 
ones  (0  mM).  What  is  more,  the  tramadol  release  rate  slowed  down  with  increasing  genipin 
concentration  (5  mM  genipin  microspheres  released  the  drug  slower  than  2  mM  genipin 
microspheres). In the case of non crosslinked microspheres, a burst effect was observed during the Mar. Drugs 2010, 8                            
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initial hour (>80% of drug) and the total amount of drug encapsulated was released after 2 h.  In 
contrast, the release of drug during the first hour from crosslinked microspheres was significantly 
lower. The amount of drug released after 2 h from microspheres crosslinked with genipin of different 
concentrations, 2 and 5 mM, was 97 and 88%, respectively, and it was completely released after 3 h. 
Therefore, as shown in preliminary studies, crosslinking with genipin controls the release of tramadol 
hydrochloride [17]. 
Figure 8. Release profiles of tramadol hydrochloride (30% w/w) in SGF from chitosan 
hydrochloride  (5  mg/mL)  microspheres  without  genipin  (0  mM)  and  crosslinked  with  
2 mM and 5 mM genipin at 50 º C for 5 h.  
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2.5.3. Low molecular weight heparin, LMWH 
Chitosan hydrochloride itself acted as a vehicle for  controlled release of LMWH. The electrostatic 
attraction between chitosan and LMWH  [18] slowed down the release of LMWH from the formed 
polyelectrolite. In addition, in this case, the release medium, PBS pH 7.4, contributed to delaying the 
drug release due to the reduced solubility of chitosan   hydrochloride  at  this pH. Thus, i n non 
crosslinked microspheres (HB), the delay in the release of the drug was the result of the formation of a 
chitosan-LMWH polyelectrolite together with reduced solubility of chitosan at release medium pH. In 
the HB release profile, an initial burst effect was observed followed by a more controlled release. This 
is in accordance with a high number of s tudies that  revealed the fastest drug release from chitosan 
microspheres at the initial  release stages [19]. After 30 minutes, 40% of the drug had been released 
from the microspheres. In the next 3 h, LMWH in the media reached 70% of the total incorporated in 
microspheres. The released drug corresponded to 90% after 4 h and it was almost completely released 
(97%) after 7 h.  
Surprisingly, no significant differences between genipin crosslinked microspheres (HGB) and non 
crosslinked microspheres (HB) were reg istered in the case of high crosslinking degree. Figure  9A 
illustrates the HGBa (25 mM genipin, 15 h, 50 º C) drug release profile as an example. As it can be 
seen, stronger crosslinking conditions were not associated with  more control over LMWH release. 
This fact could be related  to the  polymerization processes between genipin monomers. As Mi and   Mar. Drugs 2010, 8                            
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co-workers proposed [20], polymerized genipin chains could lead to wider nets in the microsphere 
matrix and, as a consequence, to less control in drug release. 
On the other hand, LMWH release kinetics corresponding to slight crosslinking conditions did not 
lead to higher control in the delivery of the drug in comparison with non crosslinked microspheres, 
HB. An example is shown in  Figure 9B, corresponding to HGBf microspheres (2.5 mM genipin, 
without thermal incubation). In this case, the absence of control over the drug release in comparison 
with  the  non  crosslinked  microspheres  could  be  explained  because  of  an  insufficient  degree  
of crosslinking. 
Figure 9. (A). Release profiles of low molecular weight heparin, LMWH, in PBS pH 7.4 
from  non  crosslinked  chitosan  microspheres  (HB)  and  with  the  highest  genipin 
crosslinking  condition,  HGBa  (25  mM  genipin,  15  h,  50  º C).  (B).  Release  profiles  of 
LMWH in PBS pH 7.4 from non crosslinked chitosan microspheres (HB) compared with 
the slightest crosslinking condition, HGBf (2.5 mM genipin, no thermal incubation).  
 
In contrast, medium crosslinking conditions, corresponding to 0.5 mM genipin incubated during 5 h 
at 50 ºC  (named HGBd), led to a more controlled release compared with HB. These were the only 
crosslinking  conditions  that  led  to  LMWH  controlled  release  within  those  assayed  in  this  study, 
summarized in Table 3. As shown in Figure 10, following a burst effect, LMWH release increased 
from 40% to 60% after 3 h in a similar way to that described for HB. Nevertheless, the drug release to 
the medium was slower throughout the period 4–8 hours. After 4 h, less than 70% of the LMWH had 
been released from medium crosslinked microspheres, which is significantly lower than 90% released 
from HB. Finally, 90% LMWH was released from HGBd after 8 hours, reaching 100% within the 
period 8–24 hours.  
The release profile registered with this drug delivery model was comparable with those obtained by 
other authors with different LMWH delivery systems. Thus, our results showed higher control in the 
release  than  that  obtained  by  some  authors  [21],  but  retained  the  drug  to  a  less  extent  than  
others [22–24]. 
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Figure 10. Release profiles of low molecular weight heparin, LMWH, in PBS pH 7.4 from 
non  crosslinked  chitosan  microspheres  and  genipin  crosslinked  microspheres  HGBd  
(0.5 mM genipin, 5 h, 50 º C). 
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3. Experimental Section  
Chitosan  hydrochloride  (HCS)  was  obtained  from  Novamatrix  (Norway).  The  degree  of 
deacetylation was 86% and the molecular weight (Mw) was 400 KDa. Clarithromycin and tramadol 
hydrochloride  were  provided  by  Vegal  Farmacé utica  S.L.  (Spain),  LMWH  was  supplied  by 
Laboratorios ROVI S.A. (Madrid, Spain) and genipin was purchased from Challenge Bioproducts Co., 
LTD. All other reagents were commercially available and used without any modification.  
3.1. Characterization of the crosslinking reaction 
A 5 mg/mL chitosan solution was prepared by disolving it in deionized water. Genipin solutions of 
different concentrations (0–5 mM) were added and the resulting mixture was incubated for different 
time  intervals  (30  min–7  h)  to  allow  the  crosslinking  to  occur,  at  50  ºC .  The  chitosan-genipin 
crosslinking reaction was characterized by UV/Vis (GBC UV/Vis 920, GBC Scientific Equipment Pty. 
Ltd., Dandenong, Australia). During the crosslinking reaction, spectra were obtained at certain time 
intervals in a wavelength range from 200 to 700 nm, at 2 nm resolution.  
3.2. Preparation of drug loaded chitosan-genipin microspheres  
The  required  amount  of  the  model  drug  with  respect  to  polymer  weight  (50%  w/w  of 
clarithromycin, 30% w/w of tramadol hydrochloride, 10% w/w of LMWH) was added to the chitosan 
solution (5 mg/mL in the case of clarithromycin and tramadol hydrochloride and 1mg/mL for LMWH) 
with constant stirring. Genipin solution was added to the chitosan solution in different concentrations 
(0–25  mM)  and  the  resulting  mixture  was  incubated  at  50  º C  during  different  time  periods  
(0 and 15 h). Drug/polymer concentration, reaction temperature, and genipin concentration ranges used 
in  each case  are  based on  previous investigations carried out in our laboratory (data  not shown). 
Chitosan-genipin-drug  solutions  were  spray-dried  using  a  Bü chi  Mini  Spray  Dryer  B-290 
(Switzerland) with a standard 0.5 mm nozzle. Briefly, spray-drying conditions were inlet temperatures 
of 150 ºC  for LMWH and 160 º C for clarithromycin and tramadol hydrochloride, spray flow rate of 
473 NL/h, aspirator air flow rate of 32 m
3/h and sample flow rate of 2.5 mL/min.  Mar. Drugs 2010, 8                            
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3.3. Morphology  
To determine shape and surface of the microspheres scanning electron microscopy (SEM) was 
used. The samples were sputter coated with Au/Pd using a vacuum evaporator (Balzers SDC  004 
Sputter coater, Oerlikon Corporate Pfä ffikon, Switzerland), and examined using a scanning electron 
microscope (JEOL JSM-6400 (JEOL, Tokyo, Japan) at 10 kV accelerating voltage. 
3.4. Zeta potential 
Microspheres  were  suspended  in  ethanol.  A  solution  of  10
-3  M  KCl  was  prepared.  1  mL  of 
microsphere suspension was diluted into 99 mL KCl solution. Zeta potential measurements were made 
by  microelectrophoresis  using  a  Malvern  Zetasizer  Nanoseries  Nano  ZS  (Malvern  Instruments, 
Herrenberg, Germany). Measurements were performed at an effective voltage of 150 V and 25 º C. 
Electrophoretic  mobility  data  were  automatically  converted  into  zeta  potential  using  the  Henry 
equation and the approximation of Helmholtz-Smoluchowski [25].  
3.5. X-ray diffraction 
X-ray diffraction patterns were obtained using an X-ray diffractometer (PHILIPS X´ PERT SW) 
with  a  copper  anode.  The  samples  were  scanned  continuously  from  0º  to  50º  (2θ)  at  45  kV  
and 40 mA. 
3.6. In vitro drug release 
Microspheres inside a cellulose dialysis bag (dialysis tubing, Mw cut off 12,000 Da, Sigma Aldrich, 
Madrid, Spain) to avoid the loss of microspheres during the experiment, were suspended in HCl 1N 
pH 1.2 as simulated gastric fluid, SGF (clarithromycin and tramadol hydrochloride) or PBS pH 7.4 
(LMWH)  without  enzyme.  The  dialysis  bag  was  placed  in  a  glass  with  50  mL  (clarithromycin),  
200 mL (tramadol hydrochloride) or 100 mL (LMWH) of the release medium at 37 º C with orbital 
agitation of 100 rpm (Rotabit horizontal shaker, Selecta, Barcelona, Spain). The volume of the release 
recipient was established on the basis of previous studies for each drug, so that the release medium 
would  not  be  saturated.  At  predetermined  interval  times,  2  mL  of  sample  were  withdrawn.  The 
withdrawn volume was replaced with fresh medium at the same temperature. The drug released was 
quantified by HPLC in the case of clarithromycin and UV/Vis in the case of tramadol hydrochloride 
and LMWH. All the experiments were carried out in triplicate.  
4. Conclusions  
The  results  of  this  study  support  the  relevance  of  genipin  as  a  valuable  natural,  non  toxic, 
crosslinking agent for controlled drug release in drug delivery systems such as chitosan hydrochloride 
microspheres. Genipin-chitosan delivery systems have shown to be useful to control the release of 
such  different  drugs  as  clarithromycin,  tramadol  hydrochloride  and  low  molecular  weight  heparin 
loaded  in  spray-dried  microspheres.  Nevertheless,  for  pharmaceutical  applications,  particular 
crosslinking conditions should be studied in each case depending on the nature of the drug, dose, Mar. Drugs 2010, 8                            
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release location in the human body, and pharmacokinetic factors, among others. Moreover, in vivo 
studies are needed to support the use of genipin for controlled drug release. 
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